Analysts on Wall Street project that Medtronic (MDT) will announce quarterly earnings of $1.24 per share in its forthcoming report, representing a decline of 0.8% year over year. Revenues are projected to reach $8.26 billion, increasing 3.5% from the same quarter last year. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. A ...

Dr. Shirin Towfigh thought she had designed a medical device that would revolutionize hernia care for women. Now, Towfigh is suing Medtronic, a global leader in medical devices, accusing the company of stealing her patented design. A Beverly Hills surgeon with over 22 years of experience, Towfigh says she discovered that a significant number of her hernia patients experiencing post-surgery complications were women — and that most mesh designs on the market were primarily tailored to the male anatomy.In 2016 ...

HONG KONG and SHANGHAI, Nov. 7, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) established a strategic partnership with Medtronic (Shanghai) Management Co., Ltd. ("Medtronic") at the 7th China International Import Expo (CIIE) held at the National Exhibition and Convention Center (Shanghai) on 6 November, 2024. Leveraging their respective strengths, the two companies will collaborate extensively on cardia ...

Medtronic plc (MDT) is scheduled to report second-quarter fiscal 2025 results on Nov. 19, before the opening bell. In the last reported quarter, the company's adjusted earnings of $1.23 exceeded the Zacks Consensus Estimate by 2.5%. Medtronic beat estimates in each of the trailing four quarters, the average surprise being 3.07%. The Zacks Consensus Estimate for fiscal second-quarter revenues is pegged at $8.26 billion, suggesting growth of 3.5% year over year. The consensus estimate for second-quarter earni ...

Financial Results Announcement - Medtronic plc will report its financial results for the second quarter of fiscal year 2025 on November 19, 2024, with a news release at approximately 5:45 a.m. CST [1] - The second quarter ended on October 25, 2024, and the summary financial information will be included in the news release [1] Webcast Details - A video webcast to discuss the second quarter results will be hosted by Medtronic at 7:00 a.m. CST on November 19, 2024 [2] - The webcast can be accessed through Medtronic's investor relations website, and a replay and transcript will be available within 24 hours of the broadcast [2] Future Reporting Schedule - Medtronic plans to report its third quarter results on February 18, 2025, and the fourth quarter results on May 21, 2025 [3] Company Overview - Medtronic is a leading global healthcare technology company headquartered in Galway, Ireland, with over 95,000 employees across more than 150 countries [4] - The company focuses on addressing challenging health problems and offers technologies that treat 70 health conditions, including cardiac devices, surgical robotics, and patient monitoring systems [4] - Medtronic's mission is to alleviate pain, restore health, and extend life, delivering innovative technologies that transform lives [4]

Healthcare Industry Overview - Defensive industries like healthcare are attractive to income investors due to their resilience during economic downturns, as medical needs are non-optional [2] - The healthcare sector is home to many excellent dividend stocks, including Merck and Medtronic [2] Merck (MRK) - Merck's shares are down by 4% this year, partly due to investor concerns about potential competition for its key cancer drug, Keytruda [3] - Keytruda, Merck's largest growth driver, faces competition from Summit Therapeutics' ivonescimab in non-small cell lung cancer (NSCLC) [3] - Keytruda will lose patent exclusivity in the U.S. in 2028, but its revenue is expected to grow until then due to FDA approvals across multiple indications [4] - Merck is developing a subcutaneous version of Keytruda, which will retain exclusivity post-2028 [4] - The company has a robust pipeline with several dozen programs and has expanded through acquisitions, such as Acceleron Pharma, leading to the approval of Winrevair for pulmonary arterial hypertension [5] - Merck collaborates with smaller companies, including Moderna, on a personalized cancer vaccine [6] - Merck's dividend payouts have increased by 71% over the past decade, with a forward yield of 2.96%, higher than the S&P 500 average of 1.32% [6] - Merck remains a reliable income stock with a strong dividend record [7] Medtronic (MDT) - Medtronic has increased its dividend payouts for 47 consecutive years, showcasing its strong business model [8] - The company operates in over 100 countries and offers a wide range of medical devices across several categories [8] - Medtronic's diabetes care segment, particularly its MiniMed 780G insulin pump with meal-detection technology, is a significant growth driver [9] - The company is developing the Hugo robotic-assisted surgery system, which could benefit from the growing demand for minimally invasive surgeries due to the aging population [9][10] - Medtronic has faced challenges in revenue growth recently but is expected to recover and continue increasing its dividend payouts in the long term [11]

Medtronic (MDT) closed the latest trading day at $90.07, indicating a +0.92% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. Meanwhile, the Dow experienced a rise of 0.69%, and the technology-dominated Nasdaq saw an increase of 0.8%.The medical device company's stock has climbed by 1.69% in the past month, exceeding the Medical sector's loss of 4.61% and the S&P 500's loss of 0.97%.Analysts and investors alike will be keeping a close eye on ...

Medtronic (MDT) closed the latest trading day at $90.60, indicating a +0.01% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.27%. Meanwhile, the Dow gained 0.65%, and the Nasdaq, a tech-heavy index, added 0.26%.Shares of the medical device company witnessed a gain of 1.42% over the previous month, beating the performance of the Medical sector with its loss of 4.14% and underperforming the S&P 500's gain of 2%.Investors will be eagerly watching for th ...

Core Insights - Medtronic announced long-term data from the SPYRAL HTN-ON MED clinical trial, demonstrating significant reductions in blood pressure for patients undergoing radiofrequency renal denervation with the Symplicity™ Spyral system compared to sham patients at two years [1][2] - The company is expanding its clinical research efforts with the SPYRAL GEMINI pilot study to investigate multi-organ denervation and the GSR-DEFINE trial to include sites in the United States [3][5] Group 1: Clinical Trial Results - The SPYRAL HTN-ON MED trial showed a treatment difference in 24-hour ambulatory systolic blood pressure (ABPM) of -5.7 mmHg (RDN group: -12.1 mmHg vs. sham group: -7.0 mmHg, p=0.039) and in office-based systolic blood pressure (OSBP) of -8.7 mmHg (RDN group: -17.4 mmHg vs. sham group: -9.0 mmHg, p=0.0034) at two years [2] - No confirmed renal artery stenosis greater than 70% was reported in the Spyral group at the two-year mark, indicating long-term safety [2] Group 2: Future Clinical Programs - The SPYRAL GEMINI pilot study will explore the safety and efficacy of multi-organ denervation in patients with uncontrolled hypertension, both on and off medications [3][4] - The GSR-DEFINE trial is an extension of the Global SYMPLICITY Registry, aiming to enroll up to an additional 2,000 patients globally across 251 sites in 55 countries [5] Group 3: Company Positioning and Commitment - Medtronic emphasizes its unique position to explore blood pressure lowering through multi-organ denervation, supported by its intellectual property and the design of the Symplicity Spyral catheter [4] - The company is committed to evidence generation and innovation in interventional hypertension treatments, reinforcing its leadership in the field [6]

With this approval, Medtronic is now the first and only company with two PFA technologies available for patients with Afib. The PulseSelect™ Pulsed Field Ablation System, which was FDA approved in December 2023, offers physicians a safe, single-shot solution for pulmonary vein isolation (PVI) while the Affera Sphere-9 catheter enables physician treatment flexibility with its wide area focal design and 9mm lattice tip that can used with an 8.5Fr sheath. "The significance of this innovative technology should ...